Evidence-graded strategy reports
Structured reports that separate approved evidence from trial findings and emerging hypotheses — so your next development decision rests on what’s actually known.
Two published reports, free to read in full.
When Biology Crosses Categories Before Medicine Does
Why biology often outruns labels, specialties, guidelines, and evidence systems. Read the report →
Metabolism as Platform Medicine
What cross-organ metabolic biology means for development strategy, endpoints, labels, reimbursement, and evidence architecture. Read the report →Two kinds of report, one standard of evidence.
Founder Reports
Flagship thesis reports that define an Integral BioStrategy framework or strategic principle. These pieces are more conceptual and cross-therapeutic, but still structured and evidence-aware.
Strategy Reports
Structured, evidence-graded analyses built around specific mechanisms, therapeutic areas, markets, endpoints, labels, and development decisions.
Related essay: The Translational Gap in Metabolic Disease defines the clinical problem behind the metabolic-integration series.
A strategy question to pressure-test?
For confidential biotech, spinout, investor, or strategic diligence inquiries, start with a brief scoping conversation.
Request a confidential scoping callPrefer email? [email protected]